A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

NCT04777409 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1840

Enrollment

INDUSTRY

Sponsor class

Conditions

Early Alzheimer´s Disease

Interventions

DRUG: Semaglutide
DRUG: Placebo (semaglutide)

Sponsor

Novo Nordisk A/S